Although the unpurified extract is reportedly an effective treatment for lupus nephritis in mice, the effects of triptolide and tripdiolide, thought to be the two most therapeutically active ...

1 The purpose of ALMS was to demonstrate the superiority of mycophenolate mofetil (MMF) over intravenous cyclophosphamide for the induction of remission in patients with lupus nephritis.

Conventional lupus nephritis (LN) treatment based on cyclophosphamide, steroids and, recently, mycophenolatemofetil has improved the outcome of the disease over the last 50 years, although failure ...

CCAR-168 is under clinical development by AbelZeta and currently in Phase I for Lupus Nephritis. According to GlobalData, Phase I drugs for Lupus Nephritis have an 84% phase transition success rate ...

GLP-1 RAs might lower kidney failure risk in patients with lupus nephritis by reducing pro-inflammatory mediators. Glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment in patients with ...

Approval in lupus nephritis is expected to push the product above the $1 billion threshold and into blockbuster sales territory. Lupus nephritis is a severe form of SLE that can lead to late-stage ...

NKX-019 is under clinical development by Nkarta and currently in Phase I for Lupus Nephritis. According to GlobalData, Phase I drugs for Lupus Nephritis have an 84% phase transition success rate (PTSR ...

Credit: Getty Images The American College of Rheumatology has released a new guideline summary for the screening, treatment, and management of lupus nephritis. The guideline authors recommend ...

Discover top medications for 'treating Lupus Nephritis'? This page compiles essential information on generic and brand-name drugs specifically used for Lupus Nephritis treatment.Here, you can ...

Aurinia Pharma and partner Otsuka have secured approval in the EU for Lupkynis, billed as the first oral treatment for active nephritis in patients with the autoimmune disease systemic lupus ...

In a new study published in Lupus Science & Medicine, researchers reviewed randomized clinical trials (RCTs) to assess therapies for initial management of lupus nephritis (LN), focusing on their ...

Objective Both belimumab and telitacicept are recognised blockers for B lymphocyte activation, both of which have been ...